News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
SilverArc Capital Management, LLC and Devesh Gandhi have filed an amended Schedule 13G, disclosing a beneficial ownership of 2,137,201 shares of TELA Bio, Inc. Class A Common Stock, representing 4.8% of the class. The filing indicates they hold shared voting and dispositive power over …
TELA Bio, Inc. missed its latest quarterly earnings expectations, reporting lower-than-anticipated revenues of US$19m and a larger loss per share of US$0.20. Following these results, analysts have reduced their 2026 revenue forecasts to US$82.4m and increased their loss per share estimates to US$0.77, leading …
TELA Bio, Inc. generated $80.28 million USD last year, with its OviTex segment being the top performer, contributing $51.22 million USD. The United States was the largest geographical contributor to the company's revenue, accounting for $68.17 million USD.
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following a significant drop in its stock price. The investigation stems from Teladoc's second-quarter 2026 financial results, which missed analyst expectations, and its subsequent downward revision of full-year revenue guidance, …
This document is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, filed by Joseph Ronald Catapano, an officer at Teladoc Health. This filing indicates a change in his beneficial ownership of securities in the company.
Martela Corporation Martela Corporation, Half year report, 12.8.2026, at 08:00 a.m. The revenue and operating result for January-June 2026 weakened compared to the same period of the previous year. April–June 2026 Revenue was EUR 14.5 million (24.6), representing a change of -41.0% Comparable operating …
Martela Corporation Martela Corporation, Inside Information, 12.8.2026 at 07:40 a.m. Due to market uncertainty and weak demand, Martela lowers its full-year revenue and result guidance. The company estimates that its revenue for 2026 will amount to approximately EUR 66–73 million and that its comparable …
TELA Bio (NASDAQ: TELA) is facing substantial doubt about its ability to continue as a going concern due to widening losses, significant cash burn, and forecasted noncompliance with debt covenants. The medical technology company reported flat revenue and an increased net loss for Q2 …
TELA Bio, Inc. reported its 2026 quarterly results with revenue of $19.29M, a net loss of ($11.26M), and diluted loss per share of ($0.2). This represents a decline in revenue compared to the prior year, primarily due to lower OviTex PRS sales, despite an …
SilverArc Capital Management, LLC and Devesh Gandhi have jointly reported a beneficial ownership stake of 4.8% in TELA BIO, INC., comprising 2,137,201 shares of Class A Common Stock. They possess shared voting and dispositive power over all these shares, with neither holding sole authority. …
TELA Bio, Inc.'s average 12-month stock price target has been lowered from $2.25 to $2.1 by 5 analysts, with individual forecasts ranging from $1 to $3 per share. Despite the cut, the new target implies a potential upside of approximately 126% from the August …
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following the company's Q2 2026 financial results, which reported lower-than-expected revenue and a reduced full-year guidance. The investigation focuses on potential claims for purchasers of Teladoc Health securities, especially after …
TELA Bio reported a significant miss on its Q2 2026 earnings, with both revenue and adjusted EPS falling short of Wall Street estimates. The company withdrew its full-year 2026 revenue guidance, citing slower sales-force productivity and weakness in its plastic and reconstructive surgery (PRS) …
TELA Bio reported Q2 2026 revenue of $19.3 million, a 4% decline year-over-year, primarily due to lower OviTex PRS volumes and price/mix headwinds. Despite an improved gross margin of 72%, the company's net loss widened to $11.3 million. Following the appointment of a new …
TELA Bio, Inc. (TELA) reported a wider-than-expected Q2 loss of $0.2 per share against an estimated loss of $0.17, and missed revenue estimates with $19.29 million compared to a $20.2 million forecast. The company's shares have underperformed the S&P 500 year-to-date, and its Zacks …
Teladoc Health's stock rose 6.7% following the acceleration of BetterHelp's nationwide insurance rollout, prompted by higher-than-expected insured demand. This shift, however, reduced the overall BetterHelp revenue outlook due to provider capacity constraints and a quicker move away from cash-pay users. The company's updated guidance …
Teladoc Health (TDOC) is a leading virtual healthcare provider facing financial challenges despite its innovative role in the sector. The company has a market capitalization of $1.21 billion, with recent revenue decline and negative EPS, yet it maintains a healthy free cash flow. Analysts …
TELA Bio, Inc., a medical technology company, has appointed Heather Getz as its new Chief Executive Officer and Director, effective August 4, 2026. Getz succeeds co-founder Antony Koblish and brings a strong track record of operational excellence and financial transformation from her previous roles …
This article provides the current stock information for Teladoc Health Inc (TDOC), including its trading price, daily change, market capitalization, and a note that more news will be available soon. It highlights that the stock closed at 7.130 USD, up 6.74%, with a market …
TELA Bio Inc is projected to report an earnings loss of 18 cents per share, according to a Refinitiv earnings preview. The article, sourced from Reuters via TradingView News, indicates that this forecast is for an upcoming earnings report.
TELA Bio, a Malvern-based medical technology company, has appointed Heather Getz as its new CEO and director, effective August 4. Getz replaces co-founder Antony Koblish and brings extensive experience in driving operational excellence and financial transformations from her previous roles at Butterfly Network and …
Levi & Korsinsky has announced a securities investigation into Teladoc Health (TDOC) after its shares dropped over 28%. This plunge followed Teladoc's report of Q2 2026 revenue below consensus and a cut in its full-year 2026 revenue guidance. The investigation focuses on potential materially …
TELA Bio Inc (TELA) is scheduled to release its Q2 2026 earnings on August 10, 2026, with revenue estimates at $20.01 million and earnings expected at -$0.18 per share. Despite a decline in full-year 2026 and 2027 revenue and earnings estimates, the company's Q1 …
Search by ticker symbol or company name and select a result to open its chart.